Annovis Bio Raises $15M in Public Stock Offering to Advance Neurodegenerative Drug Trials
Event summary
- Annovis Bio priced a $15M public offering of 7.9M shares of common stock and accompanying warrants.
- Each share and warrant was sold at a combined price of $1.90, with warrants exercisable at $2.25 per share.
- Proceeds will fund clinical development of buntanetap for Alzheimer’s and Parkinson’s diseases.
- The offering is expected to close on May 21, 2026, subject to customary closing conditions.
The big picture
Annovis Bio’s $15M offering reflects the urgent need for funding in late-stage neurodegenerative drug development. The proceeds will support buntanetap’s clinical trials, a critical phase for Annovis as it competes with other biotechs targeting Alzheimer’s and Parkinson’s. The deal underscores the high-stakes nature of neurodegenerative research, where success hinges on both scientific breakthroughs and sustained financial backing.
What we're watching
- Clinical Milestones
- How the $15M infusion will accelerate buntanetap’s Phase 3 trials for Alzheimer’s and Parkinson’s.
- Market Positioning
- Whether Annovis can sustain momentum in a competitive neurodegenerative disease space.
- Execution Risk
- The pace at which Annovis converts capital into tangible clinical progress.
Related topics